keyword
MENU ▼
Read by QxMD icon Read
search

Patient-reported outcome cancer

keyword
https://www.readbyqxmd.com/read/29776013/prognostic-pathologic-factors-in-radical-cystectomy-after-neoadjuvant-chemotherapy
#1
Fadi Brimo, Michelle R Downes, Tamara Jamaspishvili, David Berman, Guliz A Barkan, Daniel Athanazio, Schuharazad Abro, Kash Visram, Asli Yilmaz, Shraddha Solanki, Elan Hahn, Robert Siemens, Wassim Kassouf, Kiril Trpkov
We undertook a systematic evaluation of the prognostic value of numerous histologic factors in 165 radical cystectomies (RC) of patients with invasive urothelial carcinoma who underwent surgery after neoadjuvant chemotherapy (NAC). Tumor regression grade (TRG) and therapy-related stromal and epithelial changes were also recorded. Locally advanced disease (≥pT2 and/or pN+) was present in 64% of patients, 22% had no evidence of residual carcinoma (pT0+pN0) and 28% had no evidence of residual muscle invasive carcinoma (≤pT1+N0)...
May 18, 2018: Histopathology
https://www.readbyqxmd.com/read/29775792/diagnostic-yield-from-screening-asymptomatic-individuals-at-high-risk-for-pancreatic-cancer-a-meta-analysis-of-cohort-studies
#2
Juan E Corral, Karl F Mareth, Douglas L Riegert-Johnson, Ananya Das, Michael B Wallace
BACKGROUND & AIMS: There have been few studies of abdominal imaging screening of individuals at high risk for pancreatic cancer (based on family history or genetic variants). We performed a meta-analysis of prospective cohort studies to determine the diagnostic yield and outcomes of abdominal imaging screening for asymptomatic individuals at high risk. METHODS: Through a systematic review of multiple electronic databases and conference proceedings through July 2017, we identified prospective cohort studies (>20 patients) of asymptomatic adults determined to be at high-risk of pancreatic cancer (lifetime risk >5%, including specific genetic-associated conditions) who were screened by endoscopic ultrasound (EUS) and/or magnetic resonance imaging (MRI) to detect pancreatic lesions...
May 15, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29775389/systematic-review-of-the-impact-of-cancer-survivorship-care-plans-on-health-outcomes-and-health-care-delivery
#3
Paul B Jacobsen, Antonio P DeRosa, Tara O Henderson, Deborah K Mayer, Chaya S Moskowitz, Electra D Paskett, Julia H Rowland
Purpose Numerous organizations recommend that patients with cancer receive a survivorship care plan (SCP) comprising a treatment summary and follow-up care plans. Among current barriers to implementation are providers' concerns about the strength of evidence that SCPs improve outcomes. This systematic review evaluates whether delivery of SCPs has a positive impact on health outcomes and health care delivery for cancer survivors. Methods Randomized and nonrandomized studies evaluating patient-reported outcomes, health care use, and disease outcomes after delivery of SCPs were identified by searching MEDLINE, Embase, PsycINFO, Cumulative Index to Nursing and Allied Health Literature, and Cochrane Library...
May 18, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29774521/patient-reported-outcomes-of-multiple-myeloma-patients-treated-with-panobinostat-after-%C3%A2-2-lines-of-therapy-based-on-the-international-phase-3-randomized-double-blind-placebo-controlled-panorama-1-trial
#4
Paul G Richardson, Robert L Schlossman, Anuja N Roy, Ashok Panneerselvam, Suddhasatta Acharyya, Monika Sopala, Sagar Lonial
The phase 3 PANORAMA-1 trial led to regulatory approvals of panobinostat (PAN) in combination with bortezomib (BTZ) and dexamethasone (DEX) for the treatment of multiple myeloma after ≥2 prior regimens, including BTZ and an immunomodulatory drug. Patient-reported outcomes (PROs) were assessed in PANORAMA-1, with data available for 73 patients in the PAN + BTZ + DEX arm and 74 patients in the placebo (PBO) + BTZ + DEX arm. Per the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), global health status/quality of life (QoL) scores initially declined with PAN + BTZ + DEX during the first 24 weeks before approaching baseline scores and remaining steady during the next 24 weeks, with no difference between arms at Week 48...
May 17, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29774475/neuropsychological-profiles-of-breast-cancer-and-brain-tumor-cohorts-in-northeast-ontario-canada
#5
Matias Mariani, Mark William Glister Collins
PURPOSE: As developments in cancer treatment have improved outcomes, research has increasingly focused on the role of cancer-related cognitive impairment (CRCI) in quality of life for cancer survivors. Impairment profiles have been heterogeneous across studies, necessitating the study of these effects across different cohorts. The purpose of this preliminary study is to compare the memory profiles of Northeast Ontario breast and CNS cancer patients, as there is no literature which exists for profiling CRCI within this largely rural region...
May 17, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29774010/efficacy-of-vandetanib-in-treating-locally-advanced-or-metastatic-medullary-thyroid-carcinoma-according-to-recist-criteria-a-systematic-review-and-meta-analysis
#6
Pierpaolo Trimboli, Marco Castellana, Camilla Virili, Francesco Giorgino, Luca Giovanella
Background: Vandetanib is the most largely used tyrosine kinase inhibitor (TKI) in patients with locally advanced and/or metastatic medullary thyroid cancer (MTC). Here, we conducted a systematic review on its efficacy and attempted to perform a meta-analysis adopting standardized RECIST criteria as end-points. Methods: The terms "medullary thyroid" and "protein kinase inhibitor" (then including all TKIs) were searched in PubMed, ClinicalTrials...
2018: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/29773080/adjuvant-ny-eso-1-vaccine-immunotherapy-in-high-risk-resected-melanoma-a-retrospective-cohort-analysis
#7
Michael Lattanzi, Joseph Han, Una Moran, Kierstin Utter, Jeremy Tchack, Rachel Lubong Sabado, Russell Berman, Richard Shapiro, Hsin-Hui Huang, Iman Osman, Nina Bhardwaj, Anna C Pavlick
BACKGROUND: Cancer-testis antigen NY-ESO-1 is a highly immunogenic melanoma antigen which has been incorporated into adjuvant vaccine clinical trials. Three such early-phase trials were conducted at our center among patients with high-risk resected melanoma. We herein report on the pooled long-term survival outcomes of these patients in comparison to historical controls. METHODS: All melanoma patients treated at NYU Langone Health under any of three prospective adjuvant NY-ESO-1 vaccine trials were retrospectively pooled into a single cohort...
May 18, 2018: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/29772118/proms-for-pain-in-adult-cancer-patients-a-systematic-review-of-measurement-properties
#8
REVIEW
Asma A Abahussin, Robert M West, David C Wong, Lucy E Ziegler
CONTEXT: Pain is one of the most devastating symptoms for cancer patients. One-third of patients who experience pain do not receive effective treatment. A key barrier to effective pain management is lack of routine measurement and monitoring of pain. Patient-Reported Outcome Measures (PROMs) are recommended for measuring cancer pain. However, evidence to guide the selection of the most appropriate measure to identify and monitor cancer pain is limited. A systematic review of measurement properties of PROMs for pain in cancer patients is needed to identify the best validated measure for adoption to an electronic platform...
May 17, 2018: Pain Practice: the Official Journal of World Institute of Pain
https://www.readbyqxmd.com/read/29771903/incidence-demographics-and-surgical-outcomes-of-cutaneous-squamous-cell-carcinoma-diagnosed-in-northland-new-zealand
#9
Brodie M Elliott, Benjamin R Douglass, Daniel McConnell, Blair Johnson, Christopher Harmston
AIM: Non-melanoma skin cancer (NMSC) is the most commonly diagnosed and most costly cancer in Australasia. Cutaneous squamous cell carcinoma (cSCC) accounts for approximately 25% of NMSC. Despite this, reporting of cSCC is not mandatory in Australasia. This creates difficulties in planning, resourcing and improving outcomes in cSCC. Previous studies in New Zealand have lacked data on ethnicity. The aim of this study was to define the incidence and demographics of cSCC diagnosed in Northland, New Zealand, including data on ethnicity...
May 18, 2018: New Zealand Medical Journal
https://www.readbyqxmd.com/read/29771795/the-effect-of-peer-support-on-colorectal-cancer-patients-adherence-to-guideline-concordant-multidisciplinary-care
#10
Arielle E Kanters, Arden M Morris, Paul H Abrahamse, Lona Mody, Pasithorn A Suwanabol
BACKGROUND: Multidisciplinary care is critical for the successful treatment of stage III colorectal cancer, yet receipt of adjuvant chemotherapy remains unacceptably low. Peer support, or exposure to others treated for colorectal cancer, has been proposed as a means to improve patient acceptance of cancer care. OBJECTIVE: The purpose of our study was to evaluate the effect of peer support on the attitudes of patients with colorectal cancer toward chemotherapy and their adherence to it...
May 15, 2018: Diseases of the Colon and Rectum
https://www.readbyqxmd.com/read/29771723/comparing-short-term-and-oncologic-outcomes-of-minimally-invasive-versus-open-pancreaticoduodenectomy-across-low-and-high-volume-centers
#11
Robert J Torphy, Chloe Friedman, Alison Halpern, Brandon C Chapman, Steven S Ahrendt, Martin M McCarter, Barish H Edil, Richard D Schulick, Ana Gleisner
OBJECTIVE: To compare short-term and oncologic outcomes of patients with cancer who underwent open pancreaticoduodenectomy (OPD) versus minimally invasive pancreaticoduodenectomy (MIPD) using the National Cancer Database. SUMMARY BACKGROUND DATA: MIPD, including laparoscopic and robotic approaches, has continued to gain acceptance despite prior reports of increased short-term mortality when compared with OPD. METHODS: Patients with pancreatic cancer diagnosed from 2010 to 2015 undergoing curative intent resection were selected from the National Cancer Database...
May 16, 2018: Annals of Surgery
https://www.readbyqxmd.com/read/29771551/interpersonal-processes-and-intimacy-among-men-with-localized-prostate-cancer-and-their-partners
#12
Sharon Manne, Deborah A Kashy, Talia Zaider, David Lee, Isaac Y Kim, Carolyn Heckman, Frank Penedo, David Kissane, Shannon Myers Virtue
The present study focused on intimacy processes in the relationships of men diagnosed with localized prostate cancer and their partners. Using the actor-partner interdependence model (APIM), we examined the interpersonal process model of intimacy, which proposes associations between self- and perceived partner disclosure about cancer and perceived partner responsiveness as predictors of global relationship intimacy. The study's outcomes were patients' and spouses' ratings of global relationship intimacy. Both actor (my disclosure predicts my intimacy) and partner (my partner's disclosure predicts my intimacy) effects were examined, as well as possible moderating effects for cancer-related concerns...
May 17, 2018: Journal of Family Psychology: JFP
https://www.readbyqxmd.com/read/29771009/primary-tumor-sidedness-is-an-independent-prognostic-marker-for-survival-in-metastatic-colorectal-cancer-results-from-a-large-retrospective-cohort-with-mutational-analysis
#13
Sophia C Kamran, Jeffrey W Clark, Hui Zheng, Darrell R Borger, Lawrence S Blaszkowsky, Jill N Allen, Eunice L Kwak, Jennifer Y Wo, Aparna R Parikh, Ryan D Nipp, Janet E Murphy, Lipika Goyal, Andrew X Zhu, A John Iafrate, Ryan B Corcoran, David P Ryan, Theodore S Hong
Recent reports demonstrate inferior outcomes associated with primary right-sided vs left-sided colorectal tumors in patients with metastatic colorectal cancer (mCRC). We sought to describe our experience with mCRC patients on whom we have molecular data to determine whether primary tumor sidedness was an independent prognostic marker for overall survival (OS). mCRC patients with documented primary tumor sidedness who received mutational profiling between 2009 and 2014 were identified (n = 367, median follow-up 30...
May 17, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29770313/management-of-the-axilla-in-metaplastic-breast-carcinoma
#14
Brittany L Murphy, Robert T Fazzio, Tanya L Hoskin, Katrina N Glazebrook, Michael G Keeney, Elizabeth B Habermann, Tina J Hieken
Background: Metaplastic breast cancer (MBC), characterized by admixed epithelial, squamous or mesenchymal elements, constitutes <1% of breast cancers and has a poor prognosis but a paradoxically low reported rate of axillary lymph node (LN) involvement. Due to its rarity, data on appropriate axillary management is lacking, prompting this investigation of LN status and outcomes. Methods: We identified 41 MBC patients treated at our institution 2001-2011 who were followed for a median of 66 months...
April 2018: Gland Surgery
https://www.readbyqxmd.com/read/29770224/hybrid-surgery-radiosurgery-therapy-for-metastatic-epidural-spinal-cord-compression-a-prospective-evaluation-using-patient-reported-outcomes
#15
Ori Barzilai, Mary-Kate Amato, Lily McLaughlin, Anne S Reiner, Shahiba Q Ogilvie, Eric Lis, Yoshiya Yamada, Mark H Bilsky, Ilya Laufer
Background: Patient-reported outcomes (PRO) represent an important measure of cancer therapy effect. For patients with metastatic epidural spinal cord compression (MESCC), hybrid therapy using separation surgery and stereotactic radiosurgery preserves neurologic function and provides tumor control. There is currently a paucity of data reporting PRO after such combined modality therapy for MESCC. Delineation of hybrid surgery-radiosurgery therapy effect on PRO validates the hybrid approach as an effective therapy resulting in meaningful symptom relief...
May 2018: Neuro-oncology Practice
https://www.readbyqxmd.com/read/29769382/personalized-symptom-goals-and-patient-global-impression-on-clinical-changes-in-advanced-cancer-patients
#16
Sebastiano Mercadante, Claudio Adile, Gaetano Lanzetta, Kyriaki Mystakidou, Marco Maltoni, Luiz Guilherme Soares, Stefano De Santis, Patrizia Ferrera, Marco Valenti, Marta Rosati, Romina Rossi, Andrea Cortegiani, Francesco Masedu, Franco Marinangeli, Federica Aielli
BACKGROUND: The aim of this study was to assess the patients' global impression (PGI) after symptom management, as well as the achievement of personalized symptom goals (PSG). The secondary outcome was to assess related factors. Subjects, Materials, and Methods . Advanced cancer patients admitted to palliative care units rated symptom intensity by using the Edmonton Symptom Assessment Score (ESAS) at admission and then after 1 week. For each symptom, patient-reported PGI and PSG, as well as the rate of PSG response, were evaluated...
May 16, 2018: Oncologist
https://www.readbyqxmd.com/read/29768500/clinically-relevant-inflammatory-breast-cancer-patient-derived-xenograft-derived-ex-vivo-model-for-evaluation-of-tumor-specific-therapies
#17
Bedrich L Eckhardt, Maria Gagliardi, LaKesla Iles, Kurt Evans, Cristina Ivan, Xiuping Liu, Chang-Gong Liu, Glauco Souza, Arvind Rao, Funda Meric-Bernstam, Naoto T Ueno, Geoffrey A Bartholomeusz
Inflammatory breast cancer (IBC) is a rare and aggressive presentation of invasive breast cancer with a 62% to 68% 5-year survival rate. It is the most lethal form of breast cancer, and early recognition and treatment is important for patient survival. Like non-inflammatory breast cancer, IBC comprises multiple subtypes, with the triple-negative subtype being overrepresented. Although the current multimodality treatment regime of anthracycline- and taxane-based neoadjuvant therapy, surgery, and radiotherapy has improved the outcome of patients with triple-negative IBC, overall survival continues to be worse than in patients with non-inflammatory locally advanced breast cancer...
2018: PloS One
https://www.readbyqxmd.com/read/29767345/metastatic-breast-cancer-collateral-damage-project-mbccd-scale-development-and-preliminary-results-of-the-survey-of-health-impact-needs-and-experiences-shine
#18
Timothy J Williamson, Susan M Love, Jessica N Clague DeHart, Alexandra Jorge-Miller, Leah Eshraghi, Heather Cooper Ortner, Annette L Stanton
PURPOSE: Until recently, people with metastatic breast cancer (MBC) had a very poor prognosis. New treatment approaches have prolonged the time that people with MBC live, but their quality of life has received less attention. Consequently, the needs and concerns across financial, vocational, psychological, social, and physical domains in MBC patients are poorly understood-particularly regarding the collateral damage or longer-term, life-altering impacts of MBC and its treatments. This study's aims were to characterize MBC-related collateral damage, identify groups most likely to experience collateral damage, and examine its associations with psychological health, illness management, and health behaviors...
May 16, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29766829/acute-myeloid-leukemia-diagnosis-and-management-based-on-current-molecular-genetics-approach
#19
E Suguna, R Farhana, E Kanimozhi, P SaiKumar, G Kumaramanickavel, Chitralekha Sai Kumar
Background &Objective: Acute myeloid leukemia (AML) is characterized by accumulation of ?20% myeloid premature blast cells in the bone marrow and most often found in the peripheral blood. AML is generally classified based on two groups, namely, French-American-British (FAB) and World Health Organization (WHO) systems. For better clinical management, cytogenetic findings in AML are necessary and in patients with normal karyotypes, molecular analysis becomes critical. Mutations of certain genes like Nucleophosmin 1gene (NPM1), Fms-related Tyrosine Kinase 3 (FLT3), CCAAT/Enhancer Binding Protein Alpha (CEBPA), Runt-related transcription factor 1(RUNX1), and Mixed Lineage Leukemia (MLL) play a crucial role in the risk management and clinical stratification of AML patients...
May 15, 2018: Cardiovascular & Hematological Disorders Drug Targets
https://www.readbyqxmd.com/read/29766739/lingual-thyroid-carcinoma-a-case-report-and-review-of-surgical-approaches-in-the-literature
#20
William Stokes, Eric Interval, Rusha Patel
INTRODUCTION: Lingual thyroid cancer is a rare entity with a paucity of literature guiding methods of surgical treatment. Its location presents anatomic challenges with access and excision. OBJECTIVE: We present a case of T4aN1b classical variant papillary thyroid carcinoma of the lingual thyroid that was removed without pharyngeal entry. We also present a review of the literature of this rare entity and propose a treatment algorithm to provide safe and oncologic outcomes...
May 1, 2018: Annals of Otology, Rhinology, and Laryngology
keyword
keyword
112555
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"